SFC de fluidos gana $ 1,5M premio SBIR Fase II
March 4th, 2014 por Rebecca Todd
SFC Fluidics, a Fayetteville-based company led by CEO Tony Cruz, ha ganado un $1.5 million Small Business Innovation Research Phase II award from the National Institutes of Health to support the development of its MD Analyzer™ diagnostic platform.
The instrument will provide timely and clinically effective bedside monitoring of patients suffering from severe traumatic brain injury (TBI). According to the Centers for Disease Control and Prevention, desde 1997-2007, an annual average of 53,014 deaths among U.S. residents were associated with TBIs.
Current tests to monitor TBI patient conditions can take hours and sometimes days for clinical results to reach medical staff, during which time the patient could suffer from multiple organ failures or death.
“MD Analyzer™ is an advancement over current microdialysis-based diagnostics for severe TBI because all steps of the analysis will occur at bedside. Clinically actionable results will be provided in real-time every 15 minutes for metabolic biomarkers and every 60 minutes for protein detection,” dicho DR. Champak Das, SFC’s principal investigator for this Phase II project. “Availability of a nurse-friendly fully integrated system that automatically collects, analyzes and reports the dynamic changes in concentrations of clinically relevant biomarkers will significantly ameliorate the patient care in neurointensive care units.”
SFC’s collaborators at Level 1 trauma centers see real value in MD Analyzer for improving clinical decision-making and long-term patient treatment. During the Phase II project, SFC Fluidics will be targeting a pre-production prototype that is ready for Pre-Investigational Device Exemption filing by the end of the 2.5-year project. “This technology will provide critical information regarding biochemical changes inside the brain that happens during first few days after severe-to-moderate TBI,” said Das.
Anna Washurn, Coordinador de proyectos de SFC, worked extensively with Arkansas Small Business and Technology Development Center innovation consultant Rebecca Norman on the development of the SBIR Phase II proposal. Norman provided a review of SFC’s commercialization plan using agency core review criteria and worked with the center’s market research staff to provide current statistics and data to enhance this section. “ASBTDC provided TBI diagnostic market information that was used to better define our Phase II commercialization plan,” said Washburn.
SFC Fluidics is also developing other diagnostic instruments to improve the diagnosis and monitoring of brain injury patients. For more information about SFC, visit its sitio web.